Anixa Biosciences (ANIX) Competitors $3.34 -0.26 (-7.22%) Closing price 04:00 PM EasternExtended Trading$3.48 +0.15 (+4.34%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIX vs. CMPS, ORGO, SIGA, TECX, SAGE, ETON, BNTC, MREO, KMDA, and HUMAShould you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include COMPASS Pathways (CMPS), Organogenesis (ORGO), SIGA Technologies (SIGA), Tectonic Therapeutic (TECX), Sage Therapeutics (SAGE), Eton Pharmaceuticals (ETON), Benitec Biopharma (BNTC), Mereo BioPharma Group (MREO), Kamada (KMDA), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Anixa Biosciences vs. Its Competitors COMPASS Pathways Organogenesis SIGA Technologies Tectonic Therapeutic Sage Therapeutics Eton Pharmaceuticals Benitec Biopharma Mereo BioPharma Group Kamada Humacyte Anixa Biosciences (NASDAQ:ANIX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Do insiders & institutionals believe in ANIX or CMPS? 29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 25.3% of Anixa Biosciences shares are held by insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate ANIX or CMPS? Anixa Biosciences presently has a consensus target price of $9.00, suggesting a potential upside of 169.46%. COMPASS Pathways has a consensus target price of $18.83, suggesting a potential upside of 329.01%. Given COMPASS Pathways' higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than Anixa Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, ANIX or CMPS? Anixa Biosciences has higher revenue and earnings than COMPASS Pathways. Anixa Biosciences is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnixa Biosciences$210K512.31-$12.55M-$0.38-8.79COMPASS PathwaysN/AN/A-$118.46M-$1.99-2.21 Which has more risk and volatility, ANIX or CMPS? Anixa Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Does the MarketBeat Community believe in ANIX or CMPS? COMPASS Pathways received 35 more outperform votes than Anixa Biosciences when rated by MarketBeat users. Likewise, 82.14% of users gave COMPASS Pathways an outperform vote while only 75.56% of users gave Anixa Biosciences an outperform vote. CompanyUnderperformOutperformAnixa BiosciencesOutperform Votes3475.56% Underperform Votes1124.44% COMPASS PathwaysOutperform Votes6982.14% Underperform Votes1517.86% Is ANIX or CMPS more profitable? Anixa Biosciences' return on equity of -58.55% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets Anixa BiosciencesN/A -58.55% -53.29% COMPASS Pathways N/A -63.85%-51.97% Does the media prefer ANIX or CMPS? In the previous week, Anixa Biosciences had 8 more articles in the media than COMPASS Pathways. MarketBeat recorded 10 mentions for Anixa Biosciences and 2 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.87 beat Anixa Biosciences' score of 0.43 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral COMPASS Pathways 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryCOMPASS Pathways beats Anixa Biosciences on 9 of the 17 factors compared between the two stocks. Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIX vs. The Competition Export to ExcelMetricAnixa BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.59M$6.85B$5.56B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E Ratio-8.568.4326.6419.64Price / Sales512.31262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book5.666.536.974.60Net Income-$12.55M$143.25M$3.23B$248.06M7 Day Performance21.01%0.21%-0.98%-1.03%1 Month Performance25.09%10.92%7.70%3.50%1 Year Performance22.79%2.44%31.32%12.68% Anixa Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIXAnixa Biosciences3.4099 of 5 stars$3.34-7.2%$9.00+169.5%+36.4%$107.59M$210K-8.565Analyst ForecastGap UpCMPSCOMPASS Pathways2.6076 of 5 stars$4.67-2.7%$18.83+303.3%-33.9%$436.94MN/A-2.12120Positive NewsGap UpHigh Trading VolumeORGOOrganogenesis4.6111 of 5 stars$3.44+13.5%$5.50+59.9%+20.1%$436.38M$458.76M-57.33950Positive NewsAnalyst RevisionSIGASIGA Technologies2.4341 of 5 stars$6.06+0.5%N/A-18.3%$432.93M$120.33M5.0540News CoverageOptions VolumeTECXTectonic Therapeutic3.2711 of 5 stars$24.48+6.2%$80.50+228.8%N/A$430.60MN/A-4.16120Analyst ForecastGap UpSAGESage Therapeutics3.5798 of 5 stars$6.81-0.6%$8.87+30.2%-39.2%$426.45M$47.40M-1.03690ETONEton Pharmaceuticals2.3049 of 5 stars$15.85-5.9%$29.67+87.2%+299.7%$425.07M$48.33M-72.0520Positive NewsShort Interest ↑High Trading VolumeBNTCBenitec Biopharma2.5501 of 5 stars$16.17+1.1%$24.71+52.8%+113.1%$424.46M$80K-10.7120Positive NewsMREOMereo BioPharma Group1.8484 of 5 stars$2.65-3.3%$7.71+191.1%-27.4%$421.35M$1M-37.8640Analyst RevisionKMDAKamada3.8827 of 5 stars$6.97+1.8%$14.67+110.4%+35.3%$400.64M$167.24M24.89360Positive NewsShort Interest ↑HUMAHumacyte2.522 of 5 stars$2.56-1.2%$11.71+357.6%-67.2%$397.11M$517K-1.91150Analyst RevisionGap Down Related Companies and Tools Related Companies COMPASS Pathways Alternatives Organogenesis Alternatives SIGA Technologies Alternatives Tectonic Therapeutic Alternatives Sage Therapeutics Alternatives Eton Pharmaceuticals Alternatives Benitec Biopharma Alternatives Mereo BioPharma Group Alternatives Kamada Alternatives Humacyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANIX Stock Free ANIX Stock Alerts